-
α-Bungarotoxin: Nicotinic Receptor Blockade
2026-09-09
α-Bungarotoxin is a selective α7 nicotinic acetylcholine receptor antagonist used for nicotinic receptor blockade in neuroscience research and cholinergic signaling studies. In a rat placental ischemia model, α-bungarotoxin eliminated pyridostigmine-associated effects, supporting α7 nAChR dependence without establishing clinical efficacy.
-
Morin Workflows for Podocyte Energy Studies
2026-09-09
Morin combines a mechanistic role in podocyte mitochondrial research with fluorescent chelation for aluminum assays. This guide converts those properties into practical preparation, treatment, readout, and troubleshooting workflows while separating published evidence from proposed optimization steps.
-
Cediranib (AZD2171): Measure Response, Not Just Viability
2026-09-08
Cediranib (AZD2171) is a potent VEGFR-pathway probe for dissecting angiogenesis and cancer-cell responses. This article presents a response-measurement framework that separates signaling inhibition, proliferative arrest, and cell death for more informative in vitro experiments.
-
EGCG-Loaded 3D-Printed Bone Scaffolds: Study Insights
2026-09-08
The reference study integrates (-)-Epigallocatechin gallate (EGCG) with binder-jet 3D-printed tricalcium phosphate scaffolds to combine localized release with bone-regeneration, vascularization, anti-osteoclastogenic, and tumor-cell viability effects. Its in vitro results support a multifunctional scaffold concept for low-load craniofacial defects, while also showing why release kinetics and assay-specific interpretation are essential.
-
Bestatin (Ubenimex): Mechanism and Research Use
2026-09-07
Bestatin, also called Ubenimex, is an aminopeptidase inhibitor used in enzyme studies, cell-based multidrug resistance research, and plant chemical genetics. Its reported selectivity, concentration-dependent activity, and handling requirements make assay controls essential.
-
Berberine, Tuft Cells, and Estrogen-Deficiency Bone Loss
2026-09-05
A 2026 Phytomedicine study identifies an underappreciated gut–bone mechanism in which berberine increases intestinal butyrate, activates GPR41-associated tuft cell expansion, and improves barrier and immune homeostasis during estrogen deficiency. Rodent, microbiome, transcriptomic, genetic, and organoid experiments connect this pathway with reduced bone resorption, while also defining important limits for translation beyond preclinical research.
-
Biotin-azide for Reliable Cell Assay Readouts
2026-09-05
Learn how Biotin-azide (SKU A8013) can add an orthogonal, affinity-based readout to cell proliferation and cytotoxicity workflows through CuAAC labeling. This scenario-driven guide covers assay compatibility, practical optimization, interpretation limits, and evidence-based product selection.
-
Acridine Orange hydrochloride: Practical Protocol
2026-09-04
Acridine Orange hydrochloride provides differential fluorescent staining of double-helical and single-stranded nucleic acids for cytochemical workflows, including cell cycle analysis, apoptosis detection, and flow-based measurements. It is best used as a freshly prepared, validated staining reagent and should not be selected for long-term solution storage or non-nucleic-acid targets without additional validation.
-
3-Deazaneplanocin (DZNep) Workflow Guide
2026-09-04
Learn how to deploy 3-Deazaneplanocin (DZNep) in AML apoptosis, hepatocellular carcinoma sphere assays, and mechanism-linked epigenetic workflows. Practical dosing, target-engagement readouts, breast-cancer stratification principles, and troubleshooting guidance help distinguish genuine biology from assay artifacts.
-
Stable-Isotope UHPLC–MS/MS for Methylated Nucleosides
2026-09-03
The reference study introduces a stable isotope-diluted UHPLC–ESI-MS/MS workflow for sensitive, quantitative analysis of methylated purine ribonucleosides in cellular samples. Its combination of ammonium bicarbonate-assisted ionization, isomer-resolving chromatography, and methanol–SPE cleanup improves detection in complex matrices and supports future biomarker and RNA modification research.
-
Panobinostat (LBH589) Mechanistic Research Workflows
2026-09-03
Build reproducible HDAC inhibition experiments with Panobinostat (LBH589), from histone-acetylation checks to apoptosis and resistance studies. A recent scleral macrophage study also shows how this compound can connect epigenetic perturbation with extracellular-matrix remodeling beyond oncology.
-
Machine Learning Reveals New Senolytics
2026-09-02
The reference study used cost-effective machine-learning models trained only on published data to identify ginkgetin, periplocin, and oleandrin as senolytic candidates. Its workflow shows how heterogeneous literature data can prioritize compounds for human-cell validation while substantially reducing early-stage screening costs.
-
OM-MSCs Reduce Golgi Stress After Cerebral IRI
2026-09-02
This study identifies a PEDF-dependent PI3K/Akt/mTOR mechanism by which olfactory mucosa mesenchymal stem cells reduce Golgi apparatus stress after cerebral ischemia/reperfusion injury. Using complementary neuronal-cell and rat stroke models, it connects GOLPH3, SPCA1, reactive oxygen species, calcium dysregulation, Golgi fragmentation, and excessive autophagy into a therapeutically relevant pathway framework.
-
Rotenone Workflows for Complex I Research
2026-09-01
Rotenone provides a controllable way to connect mitochondrial Complex I inhibition with ROS, ATP loss, apoptosis, autophagy, and dopaminergic neurodegeneration. This guide translates the reagent into cell-based and Parkinson’s disease model workflows, with practical controls and troubleshooting for reproducible mitochondrial stress experiments.
-
Berberrubine and the Vitamin K Cycle in Thrombosis
2026-08-31
This study integrates mouse thrombosis experiments, non-targeted metabolomics, and molecular docking to investigate how berberrubine hydrochloride suppresses thrombus formation. Its principal contribution is linking the antithrombotic phenotype to vitamin K catalytic-cycle pathways and proposing VKOR and GGCX as molecular interaction sites, while distinguishing reduced thrombosis from prolonged bleeding time.